We have used Raman spectroscopy to reveal complex mechanisms in disease-state switching in low-grade AR-negative prostate cancer, demonstrating molecular pathways for targeted arrest and disruption in difficult-to-treat tumorigenic prostate cancer at the earliest possible stage. The gene discussed is AR; the disease is prostate cancer.